Financial Results for the Transition Period from September 1, 2012 to December 31, 2012
Research and development expenses for the four month transition period ended December 31, 2012, and the four month period ended December 31, 2011 were approximately $9.0 million, and $6.3 million (unaudited), respectively. The increase in research and development expenses for the four months ended December 31, 2012 compared to the four months ended December 31, 2011 relates primarily to increased product manufacture of RP103 for the potential treatment of cystinosis, Huntington's disease and non-alcoholic steatohepatitis, additional cystinosis extension and other supporting study expenses, and employee compensation, offset by a reduction in Phase 3 cystinosis clinical trial expenses.
General and administrative expenses for the four month transition period ended December 31, 2012, and the four month period ended December 31, 2011 were approximately $9.0 million, and $3.2 million (unaudited), respectively. The increase in general and administrative expenses for the four months ended December 31, 2012 compared to the four months ended December 31, 2011 relates primarily to increased expenses for pre-commercial operations requirements for RP103 for the potential treatment of cystinosis, employee compensation, stock-compensation for employees and directors, legal fees and investor relations costs.
Cash available as of December 31, 2012 was $58.4 million and included $23.4 million received from our loan agreement with HCR, $6.0 million received under an At-The-Market common stock sales agreement, and $1.8 million received from warrant exercises, in each case during the four month transition period ended December 31, 2012.About Raptor Pharmaceutical Corp. Raptor is an emerging biopharmaceutical company focused on developing and commercializing life-altering therapeutics that treat debilitating and often fatal diseases. The Company is currently focused on the development of its first product candidate, RP103 (delayed-release oral cysteamine bitartrate), as a potential treatment for nephropathic cystinosis, a rare genetic disorder. In addition to cystinosis, the Company is also testing RP103 for the potential treatment of non-alcoholic steatohepatitis, or NASH, a metabolic liver disorder, and Huntington's disease, or HD, a neurodegenerative disorder.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV